sub:assertion {
  <http://purl.obolibrary.org/obo/DOID_5419> bl:category bl:Disease .
  sub:association rdf:object <http://purl.obolibrary.org/obo/DOID_5419> ;
    rdf:predicate bl:treats ;
    rdf:subject <https://identifiers.org/drugbank:DB00433> ;
    a rdf:Statement ;
    rdfs:label "prochlorperazine maleate tablets are indicated for the control of severe nausea and vomiting prochlorperazine maleate tablets are also indicated for the treatment of schizophrenia prochlorperazine is effective for the short term treatment of generalized non psychotic anxiety however prochlorperazine maleate tablets are not the first drug to be used in therapy for most patients with non psychotic anxiety because certain risks associated with its use are not shared by common alternative treatments e g benzodiazepines when used in the treatment of non psychotic anxiety prochlorperazine maleate tablets should not be administered at doses of more than 2 mg per day or for longer than 12 weeks because the use of prochlorperazine maleate tablets at higher doses or for longer intervals may cause persistent tardive dyskinesia that may prove irreversible see warnings the effectiveness of prochlorperazine as treatment for non psychotic anxiety was established in 4 week clinical studies of outpatients with generalized anxiety disorder this evidence does not predict that prochlorperazine maleate tablets will be useful in patients with other non psychotic conditions in which anxiety or signs that mimic anxiety are found e g physical illness organic mental conditions agitated depression character pathologies etc prochlorperazine has not been shown effective in the management of behavioral complications in patients with mental retardation" ;
    bl:association_type bl:ChemicalToDiseaseOrPhenotypicFeatureAssociation ;
    bl:provided_by <https://w3id.org/um/NeuroDKG> ;
    bl:relation schema:TreatmentIndication .
  <https://identifiers.org/drugbank:DB00433> bl:category bl:Drug .
}